FDA Advisory Panel Backs Wider Compounding Access for BPC-157 and Other Peptides — What It Means

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to review seven peptides — including BPC-157, TB-500, KPV, and MOTS-c — for potential inclusion on the Section 503A Bulk Drug Substances List. Being added to this list would allow licensed compounding pharmacies to prepare these peptides for patients under a valid prescription.

The committee's vote was narrow: 8 members supported adding BPC-157, TB-500, and KPV, while 6 voted against and 1 abstained. MOTS-c passed by a 7–5 vote. It's worth noting that this is a non-binding recommendation — the FDA's own staff reviewers had argued against expanding compounding access, citing limited human safety and efficacy data, and the agency is not obligated to follow the committee's advice. A final FDA decision is still pending.

For context: in 2023, regulators had restricted the legal compounding of nearly twenty peptides, including BPC-157, over safety concerns. This week's vote signals a possible shift in that stance, driven in part by growing consumer demand and industry pressure — but it does not amount to FDA approval of these peptides as drugs, and it doesn't change how they're regulated for research use.

What this means for Zürich BioGenix customers: our products remain research-grade compounds intended strictly for laboratory and research use — not for human consumption, and not dispensed as compounded pharmacy prescriptions. This development is regulatory news worth watching for the broader peptide research field, and we'll continue to monitor the FDA's final decision and share verified updates as they become available.

Source: U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee meeting materials (July 23–24, 2026); Reuters.